JP2009515524A5 - - Google Patents
Info
- Publication number
- JP2009515524A5 JP2009515524A5 JP2008540194A JP2008540194A JP2009515524A5 JP 2009515524 A5 JP2009515524 A5 JP 2009515524A5 JP 2008540194 A JP2008540194 A JP 2008540194A JP 2008540194 A JP2008540194 A JP 2008540194A JP 2009515524 A5 JP2009515524 A5 JP 2009515524A5
- Authority
- JP
- Japan
- Prior art keywords
- polymorphism
- seq
- drug
- nucleotide position
- susceptibility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 25
- 230000033764 rhythmic process Effects 0.000 claims description 22
- 230000000747 cardiac effect Effects 0.000 claims description 20
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 19
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 19
- 101150119038 ABCB1 gene Proteins 0.000 claims description 15
- 230000005856 abnormality Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 13
- 229960003452 romidepsin Drugs 0.000 claims description 13
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 13
- 108010091666 romidepsin Proteins 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102220090100 rs1045642 Human genes 0.000 claims description 2
- 102220066605 rs1128503 Human genes 0.000 claims description 2
- 102200012755 rs2032582 Human genes 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 7
- 230000002159 abnormal effect Effects 0.000 claims 6
- 230000003247 decreasing effect Effects 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002759 chromosomal effect Effects 0.000 claims 2
- 238000005516 engineering process Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000018452 Torsade de pointes Diseases 0.000 claims 1
- 208000002363 Torsades de Pointes Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 238000003499 nucleic acid array Methods 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 16
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 16
- 102000054765 polymorphisms of proteins Human genes 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73608305P | 2005-11-10 | 2005-11-10 | |
| PCT/US2006/043656 WO2007058896A2 (en) | 2005-11-10 | 2006-11-09 | Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515524A JP2009515524A (ja) | 2009-04-16 |
| JP2009515524A5 true JP2009515524A5 (enExample) | 2010-02-04 |
Family
ID=38049148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540194A Withdrawn JP2009515524A (ja) | 2005-11-10 | 2006-11-09 | Ａｂｃｂ１多型バリアントスクリーニング、診断及び処置のための物質及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090325156A1 (enExample) |
| EP (1) | EP1957673A2 (enExample) |
| JP (1) | JP2009515524A (enExample) |
| AU (1) | AU2006315760A1 (enExample) |
| CA (1) | CA2629155A1 (enExample) |
| WO (1) | WO2007058896A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2649877A1 (en) | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| ATE490344T1 (de) * | 2006-07-14 | 2010-12-15 | Govt Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services | Abcbi-genotypisierung zur vorhersage der mikrotubuli-stabilisatorwirkstoffinduzierten toxizität |
| JP2010514801A (ja) | 2006-12-29 | 2010-05-06 | グラスター ファーマシューティカルズ， インコーポレイテッド | ロミデプシンの精製 |
| ES2725003T3 (es) | 2007-03-28 | 2019-09-18 | Signal Diagnostics | Sistema y método de análisis de alta resolución de ácidos nucleicos para detectar variaciones de secuencia |
| US10669574B2 (en) | 2008-11-18 | 2020-06-02 | XCR Diagnostics, Inc. | DNA amplification technology |
| CA2804795A1 (en) | 2010-07-12 | 2012-01-19 | Nicholas Vrolijk | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| AU2012262322B2 (en) * | 2011-05-30 | 2016-11-03 | Autotelic Llc | Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling |
| US20140349862A1 (en) * | 2011-05-30 | 2014-11-27 | Vuong Ngoc Trieu | Methods and compositions for therapeutic drug monitoring and dosing by point of care pharmacokinetic profiling |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| US10370707B2 (en) * | 2013-10-09 | 2019-08-06 | Fluoresentric, Inc. | Multiplex probes |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN105886599A (zh) * | 2014-10-20 | 2016-08-24 | 江苏所罗门兄弟医学科技有限公司 | 一种用于ABCB1基因分型的ARMS-qPCR检测试剂盒及检测方法 |
| CN108060230A (zh) * | 2018-02-07 | 2018-05-22 | 山东德诺生物科技有限公司 | 用于检测rs1045642的引物探针组及其应用 |
| CN110643699B (zh) * | 2019-10-16 | 2020-12-01 | 成都仕康美生物科技有限公司 | 一种环孢素a代谢基因检测试剂盒及其应用方法 |
| CN112980943B (zh) * | 2021-03-31 | 2022-02-08 | 山东英盛生物技术有限公司 | 一种用于检测他克莫司精准用药的方法及引物、pcr试剂和试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100814188B1 (ko) * | 1999-07-30 | 2008-03-17 | 에피다우로스 바이오테크놀로기 악티엔게젤샤프트 | 인간 ｍｄｒ-1 유전자내 다형 및 진단 및 치료에 있어서그의 용도 |
| US20040115627A1 (en) * | 2000-04-12 | 2004-06-17 | Judy Raucy | Compositions and methods for induction of proteins involved in xenobiotic metabolism |
| ATE381626T1 (de) * | 2000-04-13 | 2008-01-15 | Univ Georgetown | Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel |
| AU2002328945A1 (en) * | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
| JP2006511218A (ja) * | 2002-12-21 | 2006-04-06 | ファイザー・プロダクツ・インク | 薬物誘発性不整脈に関連する方法および組成物 |
-
2006
- 2006-11-09 AU AU2006315760A patent/AU2006315760A1/en not_active Abandoned
- 2006-11-09 US US12/093,225 patent/US20090325156A1/en not_active Abandoned
- 2006-11-09 WO PCT/US2006/043656 patent/WO2007058896A2/en not_active Ceased
- 2006-11-09 CA CA002629155A patent/CA2629155A1/en not_active Abandoned
- 2006-11-09 JP JP2008540194A patent/JP2009515524A/ja not_active Withdrawn
- 2006-11-09 EP EP06837251A patent/EP1957673A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moriya et al. | Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects | |
| JP2009515524A5 (enExample) | ||
| EP1907569B1 (en) | Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus | |
| US20080286776A1 (en) | Methods and Compositions for Assessment of Pulmonary Function and Disorders | |
| WO2006088950B1 (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
| RS53383B (sr) | Metoda za identifikaciju faktora rizika od alchajmerove bolesti | |
| JP2008529536A5 (enExample) | ||
| Lin et al. | Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene | |
| KR101633783B1 (ko) | Cyp3a5 및 cyp3a7 유전자 부위의 염기서열 다형성을 이용한 타크로리무스 혈중 약물 농도 예측 방법 | |
| CN102016031B (zh) | 高血压易感基因组的鉴定 | |
| US20120282621A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| JP2002518051A5 (enExample) | ||
| WO2001020031A2 (en) | Polymorphisms in a klotho gene | |
| US20100092468A1 (en) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents | |
| Liao et al. | Mutation analysis of the human dystrobrevin-binding protein 1 gene in schizophrenic patients | |
| US20110184044A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| Shah et al. | Monoamine Oxidase A gene polymorphisms and self reported aggressive behaviour in a Pakistani ethnic group | |
| JP4242590B2 (ja) | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 | |
| Yu et al. | Mutation screening and association study of the beta-adrenergic receptor kinase 2 gene in schizophrenia families | |
| US20230151426A1 (en) | Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) Antagonists | |
| JP6474198B2 (ja) | 内臓脂肪蓄積感受性の判定方法 | |
| JP4056212B2 (ja) | Ｇｅｆｓ＋関連遺伝子とｇｅｆｓ＋診断方法 | |
| US7851151B2 (en) | HNF-1α gene including novel single-nucleotide polymorphism, protein encoded by the HNF-1α gene, and polynucleotide, microarray, kit, and method for diagnosis of MODY3 | |
| AU2017265006A1 (en) | Methods of analysis of polymorphisms and uses thereof | |
| KR101208188B1 (ko) | 천식과 관련된 ｓｌｃ６ａ７ 유전자 다형성 |